NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 918.2 DKK | -0.16% |
|
-0.73% | +31.84% |
| 02:58pm | Novo Nordisk's Boost to Danish Employment Levels More than Expected, Economic Councils Says | MT |
| 02:31pm | Novo Nordisk Said to Defend Drug Prices Amid Heat from US Lawmakers | MT |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
919.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.84% | 594B | |
| +38.51% | 727B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +14.49% | 243B | |
| +7.55% | 205B | |
| -6.05% | 203B | |
| +6.19% | 164B | |
| +0.31% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Buys DKK5.4 Billion of Shares From Novo Holdings Under Buyback
